Hypertension Management in Renal Transplant Recipients

Hypertension is highly prevalent among renal transplant recipients and represents a leading modifiable risk factor for cardiovascular morbidity and graft loss. Its multifactorial pathogenesis encompasses effects of immunosuppressive agents, residual native kidney activity, volume overload, transplant renal artery stenosis and evolving chronic allograft dysfunction. Management frameworks stratify the immediate, early and late post-transplant periods to reveal distinct aetiologies. Optimal blood pressure targets are achieved through a combination of lifestyle measures, precise immunosuppression adjustment and pharmacotherapy directed principally at the renin–angiotensin system. For resistant cases, adjunctive interventions such as native nephrectomy or renal denervation may offer benefit. Robust control of blood pressure underpins improved patient and graft survival globally.

Research from Nature Portfolio

A large retrospective analysis of over 800 renal transplant recipients demonstrated that maintaining a mean systolic blood pressure below 130 mmHg was associated with a significant reduction in a composite of patient and graft mortality compared with targets of 130–139 mmHg or ≥140 mmHg. Lower targets proved safe and correlated with better long-term outcomes, supporting the adoption of more intensive control in this population. Complementary work using tandem mass spectrometry revealed persistent intrarenal synthesis of angiotensin II despite systemic blockade, with a progressive increase in chymase-dependent formation over successive transplant vintages. This distortion of the intragraft renin–angiotensin system highlights chymase as a potential therapeutic target and identifies neprilysin as central to the alternative pathway.

Hypertension Management in Renal Transplant Recipients publication trend

The graph below shows the total number of articles in hypertension management in renal transplant recipients across all publications each year (not limited to Nature Index journals).

Technical terms

Renin–angiotensin system (RAS): Hormonal cascade that regulates blood pressure and fluid balance primarily via angiotensin II.

ACEI: Angiotensin-converting enzyme inhibitor, a class of drugs reducing angiotensin II formation.

ARB: Angiotensin receptor blocker, a class of drugs preventing angiotensin II binding to its receptor.

Systolic blood pressure (SBP): Peak arterial pressure during cardiac contraction.

Graft survival: Duration until loss of function of the transplanted organ.

Hyperkalaemia: Elevated serum potassium level, a potential adverse effect of RAS blockade.

Transplant renal artery stenosis (TRAS): Narrowing of the artery supplying the transplanted kidney, often causing resistant hypertension.

References

1. Safety of ACEI/ARB use in the early (. Frontiers in Pharmacology (2024).
2. Approach and Management of Hypertension After Kidney Transplantation. Frontiers in Medicine (2020).
3. Intensive blood pressure control is associated with improved patient and graft survival after renal transplantation. Scientific Reports (2019).
4. Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation. Scientific Reports (2019).